Document:

Consulting Agreement by & between Curis and Dr. Stephen Carter

 Exhibit 10.19 
 CONSULTING AGREEMENT 
 This Consulting Agreement, effective as of May 11, 2007, is between
Curis, Inc., having a place of business at 45 Moulton Street, Cambridge, MA 02138 (“Curis”), and Dr. Stephen K. Carter, having an address at 263 West End Avenue, New York City, New York 10023 (“Consultant”).

 WHEREAS, Curis desires to have the benefit of Consultant’s knowledge and experience, and Consultant desires to provide consulting
services to Curis as provided in this Agreement; 
 NOW, THEREFORE, in consideration of the promises set forth in the Agreement, Curis and
Consultant hereby agree as follows: 
  

	1.	Term. The term of this Agreement shall be for a period of one year from the effective date or until earlier terminated by either party. Either party may terminate the
Agreement by providing thirty (30) days prior written notice to the other party. 

  

	2.	Consulting duties. 

  

	 	(a)	During the term, Consultant shall provide Curis or to Curis’ designee, in accordance with the specifications outlined in the attached Project Exhibit A, and any other Project
Exhibits which may be attached hereto from time to time, as agreed to in writing by both parties, such consulting services at such times and places as Curis may from time to time request. Curis shall give Consultant reasonable advance notice of any
service required. 

  

	 	(b)	All work to be performed by Consultant for Curis shall be under the general supervision of Curis’ Chief Executive Officer or his designee. 

  

	 	(c)	Consultant shall devote his best efforts and ability to the performance of the duties attaching to this obligation, devoting an amount of time as mutually agreed. All work performed
by Consultant for Curis shall be at times reasonably convenient to him/her. Consultant agrees to furnish Curis with written reports with respect to such consulting services if and when requested by Curis. 

  

	3.	Compensation. In consideration for the services rendered by Consultant to Curis during the Term, Curis shall pay Consultant compensation in the amount of Two Thousand dollars
($2000.00) per day for each day of consulting work, or Two Hundred and Fifty dollars ($250.00) per hour for portions thereof of consulting work performed on behalf of Curis, not to exceed $20,000 dollars for the term of this Agreement unless as
otherwise agreed to by Curis. Payment of such amounts will be made upon Curis’ approval of a detailed invoice from Consultant. Curis shall reimburse Consultant for reasonable out-of-pocket expenses incurred in the performance of his duties
hereunder as requested by Curis upon presentation of reasonably detailed receipts. 

  

	4.	Status. Consultant’s relation to Curis shall be that of an independent contractor and neither this Agreement nor the services to be rendered hereunder shall for any
purpose whatsoever or in any way or manner create any employer-employee relationship between the parties. Consultant shall not be deemed an agent for any purpose and shall have no authority to bind Curis. 

  

	5.	Inventions, Proprietary Rights and Disclosures. 

  

	 	(a)	 Consultant agrees to disclose promptly to Curis all inventions, discoveries, designs, improvements and all other intellectual property rights (collectively referred
to as “Inventions”) made or perfected in the performance of, or arising out of, the work to be performed by Consultant for Curis, and will maintain adequate and current written records (in the form of notes, sketches, drawings and as may
be specified by Curis), properly corroborated, to document the conception and/or first actual reduction to practice of any Invention. Such written records shall be available to and remain the sole property of Curis at all times. All such Inventions
and patents therefor shall be the exclusive property of Curis. Consultant 

  

 1 

	 	 
hereby undertakes and agrees to execute such assignments and other papers which, in the opinion of Curis, are necessary at any time to permit the filing and
prosecution of copyrights, applications for copyrights, applications for patents covering the Inventions or are otherwise required for compliance with the provisions of this paragraph. 

  

	 	(b)	Consultant agrees that the services furnished pursuant to the work to be performed hereunder, the data and Inventions generated by the said work and any and all information, data,
specifications, techniques, formulae and processes disclosed by Curis in connection therewith (collectively referred to as “Confidential Information”) are the property of Curis and are confidential and proprietary to Curis. Consultant
agrees that he/she shall not use Confidential Information for any purpose other than as advised or directed by Curis regardless of whether such Confidential Information has been furnished or made available to Consultant by Curis or is original with
Consultant. Without Curis’ express written consent first obtained, Consultant agrees that he/she shall not disclose or make available any Confidential Information to any third party regardless of whether such Confidential Information has been
furnished or made available to Consultant by Curis or is original with Consultant. Consultant shall not discuss the nature of his activities in connection with Curis with anyone except authorized representatives of Curis. At Curis’ request,
Consultant shall provide Curis with all Confidential Information furnished to Consultant by Curis or original with Consultant in connection with his services furnished hereunder which has been reduced to writing and retain no copies thereof.
Consultant understands that in receiving Confidential Information, he/she receives no right to a license, implied or otherwise, under any patent or other rights now or hereafter owned or controlled by Curis. 

  

	 	(c)	The foregoing obligations of confidentiality and non-use shall not apply to: 

  

	 	(1)	information which at the time of disclosure by Curis hereunder to Consultant or at the time of generation by Consultant is in the public domain; 

  

	 	(2)	information which after disclosure by Curis to Consultant or generation by Consultant is published or otherwise becomes part of the public domain through no fault of Consultant, but
only after it is so published or so becomes part of the public domain; 

  

	 	(3)	information received by Consultant from a third party who is legally in possession of the same and not under an obligation of confidentiality with respect thereto; or

  

	 	(4)	information which was already in Consultant’s possession at the time of receipt from Curis, as evidenced by written records; 

 however, Confidential Information shall not be deemed within the foregoing exceptions if 
  

	 	(i)	specific information is merely embraced by more general information in the public domain or Consultant’s possession, or 

  

	 	(ii)	it constitutes a combination which can be reconstructed from multiple sources in the public domain or Consultant’s possession, none of which shows the whole combination of the
Confidential Information. 

  

	 	(d)	Consultant warrants and represents that no trade secrets or other confidential information of any other person, firm, corporation, institution or other entity will be wrongfully
disclosed by him/her to Curis in connection with any of the services called for hereunder. Consultant further warrants and represents that none of the provisions of this Agreement, nor the services which will be performed by Consultant pursuant to
the work to be performed hereunder, contravenes or is in conflict with any agreement of Consultant with, or obligation to, any other person, firm, corporation, institution or other entity including, without limiting the generality of the foregoing,
employment agreements, consulting agreements, disclosure agreements or agreements for assignment of inventions. Consultant agrees that his services to other enterprises may result in a conflict of interest with his obligations to Curis under this
Agreement, and agrees to inform Curis of his services to other enterprises and, in the case of conflict of interest, to immediately inform Curis and resolve the conflict in a mutually satisfactory manner. 

  

 2 

	6.	Survival of Provisions. The provisions of paragraph 5 hereof shall survive the termination or expiration of this Agreement. 

  

	7.	Assignability and Binding Effect. Neither this Agreement nor any interest shall be assignable by either party unless such assignment is mutually agreed to in writing by the
parties hereto; provided, however, that Curis may assign this Agreement to any corporation with which Curis may merge or consolidate or to which Curis may assign substantially all of its assets or that portion of its business to which this Agreement
pertains without obtaining the agreement of Consultant. 

  

	8.	Headings. The paragraph headings contained herein are included solely for convenience of reference and shall not control or affect the meaning or interpretation of any of the
provisions of this Agreement. 

  

	9.	Notices. Any notices or other communications hereunder by either party shall be in writing and shall be deemed to have been duly given if delivered personally to the other
party or sent by registered or certified mail, return receipt requested, to the other party at the following addresses: 

  

			
	If to Curis:	  	 Curis, Inc.
 45 Moulton Street

Cambridge, MA 02138
 Attention: Legal Department

	  
	  
	  
		
	If to Consultant:	  	 Dr. Stephen K. Carter

	  
	  
	  
	  

  

	    	or at such other address as such other party may designate in conformity with the foregoing. 

  

	10.	Entire Agreement; Modification. This document sets forth the entire Agreement between the parties hereto with respect to the subject matter hereof. This Agreement shall not
be changed or modified in any manner except by an instrument signed by the duly authorized officers of each of the parties hereto, which document shall make specific reference to this Agreement and shall express the plan or intention to modify same.

  

	11.	Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument. 

 IN WITNESS WHEREOF, this Agreement is executed under seal by both parties and deemed to be governed by the
laws of the Commonwealth of Massachusetts, exclusive of its conflicts of law principles. 
  

									
	CURIS, INC.	 		 	CONSULTANT:
					
	By:	 	 /s/ MICHAEL P.
GRAY        
	 		 	By:	 	 /s/ STEPHEN K. CARTER

	Name:	 	Michael P. Gray	 		 	Name:	 	Stephen K. Carter
	Title:	 	COO and CFO	 		 	SS#:	 	[Insert #]

  

 3 

 Exhibit A 
 During the term of this agreement, Dr. Carter shall provide to Curis or to Curis designee consulting services for Curis’ Targeted Cancer Drug Development programs, including pre-clinical development, clinical development, and
strategic planning for advancing Curis’ drug candidates into and through the clinic. Consulting services will be provided at such times and places as Curis may from time to time request. These services may include, but are not limited to the
development of IND packages, clinical documents, protocols and timelines, and intellectual property summaries for potential in-licensing opportunities Curis is considering. Curis shall give Dr. Carter reasonable advance notice of any service
required. Dr. Carter agrees to furnish Curis with written reports with respect to such consulting services if and when requested by Curis. 
  

 4Employment Agreement

 Exhibit 10.18 
 EXECUTIVE EMPLOYMENT AGREEMENT 
 THIS EMPLOYMENT AGREEMENT (“Agreement”) is made and
entered into as of January 9, 2008 by and between NovaBay Pharmaceuticals, Inc. (“Company”) and Thomas J. Paulson (“Executive”). 
 RECITAL 
 The Company and Executive desire to formalize and reflect Executive’s employment under
the terms and conditions of this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing recital, the mutual covenants herein
contained and for other good and valuable consideration, the parties hereto hereby agree as follows: 
  

	I.	EMPLOYMENT. 

 A. Position and
Responsibilities. The Company hereby employs the Executive as its Chief Financial Officer (“CFO”). Executive shall do and perform all such services and acts as necessary or advisable to fulfill the duties and obligations of said
position and/or such other and/or additional responsibilities as reasonably delegated to Executive by Executive’s superior and/or the Company’s Board of Directors (the “Board”) typically performed by a CFO consistent with the
Company’s Bylaws. 
 B. Term. Executive’s employment with the Company is at-will and shall be governed by the terms of this
Agreement, commencing on January 9, 2008 and continuing to and including December 31, 2011, unless this Agreement is terminated at some earlier time in accordance with the terms of this Agreement. 
 C. Devotion. Except as heretofore or hereafter excepted by the Company in writing, during the term of this Agreement, Executive (i) shall
devote full time and attention to the foregoing responsibilities, (ii) shall not engage in any other business or other activity which may materially interfere with Executive’s performance of said responsibilities, and (iii) except as
to any investment made in a publicly traded entity not amounting to more than 1% of its outstanding equity, shall not, directly or indirectly, as an employee, consultant, partner, principal, director or in any other capacity, engage or participate
in any business that is in competition with the Company. 
 D. Services’ Uniqueness. It is agreed that Executive’s services
to be performed under this Agreement are special, unique and extraordinary and give rise to peculiar value, the 

  

 NOVABAY PHARMACEUTICALS, INC. 

					
	5980 Horton St., Ste 550	 	 	  	 (510) 595-1100 x150
	Emeryville, CA 94608	 	 	  	 Fax: (510) 740-3629

 rnajafi@novabaypharma.com 

 
loss of which may not be reasonably or adequately compensated by a damages award, in any legal action. Accordingly, in addition to any other rights or
remedies available to the Company, the Company shall be entitled to injunctive and other equitable relief to prevent or remedy a breach of the terms of this Agreement by Executive. 
  

	II.	PROPRIETARY RIGHTS, CONFIDENTIAL INFORMATION, NONSOLICITATION, ETC.  

 Executive has executed an agreement relating to the treatment of (and Executive’s obligations as to) proprietary rights, confidential information, and certain non-solicitation and other matters. It is further
understood and agreed that said agreement is deemed to continue in full force and effect, binding and not affected, in any manner, by the terms in this Agreement. 
  

	III.	COMPENSATION AND BENEFITS. 

 Executive’s
compensation and bonus rights are as follow: 
 A. Salary. Executive shall be entitled to an annual salary of $250,000(subject to such
deductions, withholding and other charges as required by law), payable in accordance with the Company’s standard payroll schedule. Executive’s salary shall be subject to at least an annual review by the Company and may be adjusted by
action of the Board, based on your performance, the financial performance of the Company and the compensation paid to a CFO (in comparable positions). Such adjustment shall not reduce your then current annual base salary unless you provide written
consent. 
 B. Bonus. The Executive shall be eligible for any bonus plan that is deemed appropriate by the Board of Directors of the
Company. 
 1. Annual Bonus. Executive shall be entitled to such
amount of bonus payment, if any, as considered and approved by the Board annually (for each year of services) during the term of this Agreement, which bonus amount shall be determined by all factors deemed relevant for that purpose by Board and
shall include (i) the fulfillment, during the relevant year, of specific milestones and tasks delegated, for such year, to Executive as set by Executive and the Company’s President and/or the Board, before the end of the first calendar
Quarter (ii) the evaluation of Executive by the Company’s President and/or the Board, (iii) the Company’s financial, product and expected progress and (iv) other pertinent matters relating to the Company’s business and
valuation. The amount of any annual bonus determined with respect to performance during a calendar year or the Company’s fiscal year, as the case may be, will be paid in full on or before the date that is 2 1/2 months following the end of the year for which the bonus was earned. 
  

 NOVABAY PHARMACEUTICALS, INC. 

					
	5980 Horton St., Ste 550	 	 	  	 (510) 595-1100 x150
	Emeryville, CA 94608	 	 	  	 Fax: (510) 740-3629

 rnajafi@novabaypharma.com 

 C. Stock Options. The Company will recommend to the Board of Directors to issue to Executive options to
purchase 200,000 of the Company’s Common shares (the “Options”). The Company will make the recommendation to grant these options at the next regularly scheduled meeting of the Board of Directors at an exercise price equivalent to the
Fair Market value on the date of the grant. The Fair Market Value of a Share as of a given date shall be the closing price of one share as reported on the American Stock Exchange (AMEX) on such date or, if the American Stock Exchange is not open for
trading on such date, on the most recent preceding date when it is open for trading. 
  

	 	•	 	 Twenty-five percent (25%) of the Options or 50,000 will vest on the January 2, 2009 and 6.25% of the Options or 12,500 will vest quarterly thereafter for
12 quarters commencing on April 2, 2009. The Options are valid for 10 years for so long as the Executive remains an employee of the Company. Executive shall be required to sign an Option Agreement between Executive and Company and the vesting
and exercise of the Options shall be subject to the terms of the Option Agreement and the applicable Company stock option plan. Notwithstanding the above, the option rights shall become fully exercisable in the event that Company is acquired by an
independent entity by a merger, sale of assets or similar transaction (or series of related transactions), as more fully set forth in the definition of “change of control” herein other than by the issuance and sale of its stock by Company
for capital raising purposes, 

 D. Other Benefits. Executive shall be entitled to five (5) weeks of said
vacation for each calendar year to be taken pursuant to the Company’s vacation benefits policy. Executive is also entitled to other benefits as (i) are generally available to the Company’s other similar, high level, executives,
consisting of such medical, retirement and similar benefits as are so available and (ii) are deemed special to Executive and approved by the Board. 
  

	IV.	TERMINATION. 

 A. At-Will Employment. It is
understood and agreed by the Company and Executive that this Agreement does not contain any promise or representation concerning the duration of Executive’s employment with the Company. Executive specifically acknowledges that his employment
with the Company is at-will and may be altered or terminated by either Executive or the Company at any time, with or without cause and with or without notice. In addition, that the rate of salary, any bonuses, paid time off, other compensation, or
vesting schedules are stated in units of years or months or weeks does not alter the at-will nature of the employment, and does not mean and should not be interpreted to mean that Executive is guaranteed employment to the end of any period of time
or for any period of time. In the event of conflict between this disclaimer and any other statement, oral or written, present or future, concerning terms and conditions of employment, the at-will relationship confirmed by this disclaimer shall
control. This at-will status cannot be altered except in a writing signed by Executive and approved by the Board. 
  

 NOVABAY PHARMACEUTICALS, INC. 

					
	5980 Horton St., Ste 550	 	 	  	 (510) 595-1100 x150
	Emeryville, CA 94608	 	 	  	 Fax: (510) 740-3629

 rnajafi@novabaypharma.com 

 B. Termination of Employment. Although Executive’s employment hereunder shall be deemed
“at will,” any termination shall be subject to the following terms: 
 1. For Cause. In the event that
Executive is terminated for cause (as hereinafter defined) after at least 12 months of employment with the Company , Executive shall be entitled an amount equal to $15,000 which will be paid in a lump sum within 60 days of such termination for
cause. This amount is in addition to Executive’s earned wages through the date his employment with the Company is terminated, his accrued but unused vacation, reimbursements of his outstanding expenses incurred and submitted in compliance with
Company policies and any other portion of his compensation earned through the termination date. 
 2. Without Cause. If
the Executive had been employed for at least four (4) years and Executive is terminated without cause, as hereinafter defined, Executive shall be entitled to an amount equal to one (1) year of the rate of salary then being paid to
Executive as of the date of such termination plus the amount of the bonus (if any) paid or payable to Executive relative to services performed by Executive during the previous calendar year. In the event that Executive has less than four years of
service with the Company, Executive shall be entitled to the following: 
  

	 	a.	three (3) months of base salary and bonus for each one full year of employment, plus 

  

	 	b.	for any partial years, one of the following: (i) one month of base salary and bonus if Executive was employed up to three (3) months of the partial year or
(ii) two (2) months of base salary and bonus if Executive was employed for 4 to 11 months of the partial year. 

 Amounts payable under this Section IV.B.2 shall be paid as follows: 
 i. If the Executive has accrued twelve months of separation pay, the Executive will be paid in seven installments, the first of which shall be paid on the 183rd day after the date of termination and the second to seventh installment shall be paid monthly thereafter. The first installment shall be equivalent to one-half to the amount due the Executive and the remaining half
shall be paid in six equal monthly installments thereafter. 
 ii. If
the Executive has accrued nine months of separation pay, the Executive will be paid in four installments, the first of which shall be paid on the 183rd day after the date of termination.and the second to fourth installments shall 

  

 NOVABAY PHARMACEUTICALS, INC. 

					
	5980 Horton St., Ste 550	 	 	  	 (510) 595-1100 x150
	Emeryville, CA 94608	 	 	  	 Fax: (510) 740-3629

 rnajafi@novabaypharma.com 

 
be paid monthly thereafter. The first installment shall be equivalent to six months or 6/9 of the entire separation pay and the remaining 3/9 shall be paid
in three equal monthly installments thereafter. 
 iii. If the
Executive has accrued eight months of separation pay, the Executive will be paid in three installments, the first of which shall be paid on the 183rd day after the date of termination.and the second to third installments shall be paid monthly thereafter. The first installment shall be equivalent to six months or 6/8 of the entire separation pay and the remaining 2/8 shall be paid in
equal monthly installments thereafter. 
 iv. If the Executive has
accrued seven months of separation pay, the Executive will be paid in two installments as the case maybe, the first of which shall be paid on the 183rd day after the date of termination.and the second installment shall be paid a month thereafter. The first installments shall be equivalent to six months or 6/7 of the entire separation pay and the remaining 1/7 shall be paid a month
thereafter. 
 v. If the Executive has accrued six months or less of
separation pay, the separation pay will be paid in full on the 183rd day after the termination date. 
 Notwithstanding any provisions to the contrary, if Executive is Terminated Without Cause by the Company and Ron Najafi is no longer the Chief Executive Officer of the
Company at the time of such termination, Executive shall be entitled to an amount equal to one year of the rate of salary then being paid to Executive as of the date of such termination and bonus. 
 C. Related Provisions. The following terms, conditions and definitions shall apply to the termination of Executive: 
 1. “Termination Without Cause.” For purposes of Section IV.B above, a termination without cause shall be deemed to
constitute any termination of Executive’s employment hereunder by the Company, or by Executive, other than a termination for cause as defined below. Notwithstanding any contrary provision herein, it is understood that a termination without
cause also shall include a termination which either: 
 (a) occurs due to the death of Executive or to any physical or mental
Long-Term Disability that would prevent the performance of Executive’s duties under this Agreement. For the purposes of this Agreement, a “Long-Term Disability” shall mean a long-term disability that after consideration and
implementation of reasonable accommodations (provided that no accommodation that imposes undue hardship on the Company will be 

  

 NOVABAY PHARMACEUTICALS, INC. 

					
	5980 Horton St., Ste 550	 	 	  	 (510) 595-1100 x150
	Emeryville, CA 94608	 	 	  	 Fax: (510) 740-3629

 rnajafi@novabaypharma.com 

 
required), renders or will render Executive unable to perform his essential job functions for a period longer than four consecutive months. The determination
of Executive’s Long-Term Disability shall be made by Executive’s attending physician unless the Board disagrees with such determination, in which case Executive’s Long-Term Disability shall be determined by a majority of three
physicians qualified to practice medicine in the State of the Executive’s residence, one to be selected by each of the Executive (or his authorized representative) and the Board and the third to be selected by such two designated physicians;

 (b) occurs without cause by the Company or for Constructive Termination by Executive, within ninety (90) days prior to
a Change of Control or one (1) year following a Change of Control; or 
 (c) is a Constructive Termination (as defined
below) initiated by Executive. 
 A “Change in Control” means the occurrence of any of the following events: (i) any sale or
exchange of the capital stock by the shareholders of the Company in one transaction or series of related transactions where more than 50% of the outstanding voting power of the Company is acquired by a person or entity or group of related persons or
entities; or (ii) any reorganization, consolidation or merger of the Company where the outstanding voting securities of the Company immediately before the transaction represent or are converted into less than fifty percent 50% of the
outstanding voting power of the surviving entity (or its parent corporation) immediately after the transaction; or (iii) the consummation of any transaction or series of related transactions that results in the sale of all or substantially all
of the assets of the Company; or (iv) reverse merger; or (v) any “person” or “group” (as defined in the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) becoming the “beneficial
owner” (as defined in Rule 13d-3 under the Exchange Act) directly or indirectly of securities representing more than fifty percent (50%) of the voting power of the Company then outstanding; or (vi) less than a majority of the current
Board of Directors are persons who were either nominated for election by the current Board of Directors or were elected by the current Board of Directors. 
 “Constructive Termination” shall mean (i) the assignment or partial assignment of any duties or responsibilities inconsistent in any respect with those customarily associated with the position or those
actually provided this agreement (including status, offices, titles and reporting requirements) to be held by you during your employment period, or any other action by the Company that results in a diminution or other reduction or any adverse change

  

 NOVABAY PHARMACEUTICALS, INC. 

					
	5980 Horton St., Ste 550	 	 	  	 (510) 595-1100 x150
	Emeryville, CA 94608	 	 	  	 Fax: (510) 740-3629

 rnajafi@novabaypharma.com 

 
in your position, title, authority, duties or responsibilities; (ii) any failure by the Company to comply with any provision of this agreement;
(iii) a relocation of your principal place of employment more than thirty-five (35) miles from its current location; (iv) any reduction in your base salary or bonus opportunity; (v) a reduction in the kind or level of your
benefits to which you were entitled immediately prior to such reduction; (vi) a material reduction of the facilities and perquisites (including office space and location) or secretarial and administrative support available to you immediately
prior to such reduction; (vii) the assignment of duties that are substantially inconsistent with your training, education, professional experience and the job for which you were initially hired hereunder; or (viii) the failure of any
successor-in-interest to assume all of the obligations of the Company under this agreement. 
 2. “Termination For
Cause.” Subject to the notice requirement as provided in paragraph E below, for purposes of Section IV.B.2 (and Section IV.C.1) above, a termination for cause shall be a termination of Executive’s employment hereunder made: 

(a) by the Company, if Executive: 
 (i) materially breaches any material terms of this Agreement which has caused demonstrable injury to the Company 
 (ii) commits willful gross acts of dishonesty, fraud, misrepresentation, or other acts of moral turpitude taken by Executive in connection with Executive responsibilities as an employee and intended to result in
substantial personal enrichment; or 
 (iii) is convicted of any felony or any crime involving moral turpitude resulting in
either case in significant and demonstrable economic harm to the Company, provided that no act or failure to act shall be considered “willful” under this definition unless you acted, or failed to act, with an absence of good faith and
without a reasonable belief that your action, or failure to act, was in the best interest of the Company; 
 (b) by Executive,
unless such termination by Executive is for Constructive Termination. 
 D. Company Actions. All relevant determinations to be made by
the Company under paragraph C.2(a) above shall be made in the reasonable discretion of the Board (or, if so delegated by said Board, by a committee of the Board), acting in good faith, and, except as otherwise specified herein, shall be conclusive
and binding, but shall be subject to arbitration in accordance with Section V below. This Agreement is intended to comply with the 

  

 NOVABAY PHARMACEUTICALS, INC. 

					
	5980 Horton St., Ste 550	 	 	  	 (510) 595-1100 x150
	Emeryville, CA 94608	 	 	  	 Fax: (510) 740-3629

 rnajafi@novabaypharma.com 

 
requirements of Internal Revenue Code Section 409A (“Section 409A”) and the Board and the Board committee will interpret its provisions
accordingly. Executive understands and agrees that the Company makes no assurances with respect to the tax consequences arising as a result of this Agreement and the payment of any tax liabilities or related penalties arising out of this Agreement
is solely and exclusively the responsibility of Executive, without any expectation or understanding that the Company will pay or reimburse Executive for such taxes or other items. Concerning any Section 409A taxes or related penalties the
Company will use its best efforts in good faith to reduce or eliminate such tax liabilities or penalties including but not limited to a delay of such payments the minimum time necessary to avoid tax liabilities or penalties. If any payment is
delayed pursuant to this paragraph on the date of payment the Company shall pay in a lump sum all payments that otherwise would have been paid during the period of the delayed payments. 
 E. Notice and Remedy. In the event that any reason for termination by the Company under paragraph C.2(a) above, or by Executive under paragraph
C.2(b) above, may be cured by Executive, or the Company, as the case may be, then the Company, or Executive, shall first give a written notice to the other (by mail, or by email, or by fax, to the last known address of the recipient; said notice
being deemed given, if by mail, as of the earlier of four days after mailing or as of the date when actually received, or, if by email or fax, when sent), specifying the reason for termination and providing a period of 30 days to cure the fault or
reason specified. Lacking such cure within said 30 days, or if the notified party earlier refuses to effect the cure, the termination shall then be deemed effective. If such cure is so made, the termination shall not then be deemed effective, but
any later conduct of a similar nature constituting a reason for termination shall allow the Company, or Executive, as the case may be, the right to cause the termination effectiveness without need for any further period of time to cure. All
communications shall be sent to the address as set forth on the signature page hereof, or to such other address as a party may designate by ten days’ advance written notice to the other party hereto. 
  

	V.	ARBITRATION. 

 A. Arbitration. Any
controversy or claim arising out of or relating to this Agreement, or the breach thereof, or any of the rights, benefits or obligations resulting from its terms, shall be settled by arbitration in San Francisco, California. . Except for the right of
the Company and Executive to seek injunctive relief in court, any controversy, claim or dispute of any type arising out of or relating to Executive’s employment or the provisions of this Agreement shall be resolved in accordance with this
Section V of the Agreement, regarding resolution of disputes, which will be the sole and exclusive procedure for the resolution of any such disputes. This Agreement shall be enforced in accordance with the Federal Arbitration Act, the enforcement
provisions of which are incorporated by this reference. Matters subject to these provisions include, without limitation, claims or disputes based on statute, contract, common law and tort and will include, for example, matters pertaining to
termination, discrimination, harassment, compensation and benefits. Matters to 

  

 NOVABAY PHARMACEUTICALS, INC. 

					
	5980 Horton St., Ste 550	 	 	  	 (510) 595-1100 x150
	Emeryville, CA 94608	 	 	  	 Fax: (510) 740-3629

 rnajafi@novabaypharma.com 

 
be resolved under these procedures also include claims and disputes arising out of statutes such as the Fair Labor Standards Act, Title VII of the Civil
Rights Act, the Age Discrimination in Employment Act, the California labor code, and the California Fair Employment and Housing Act. Nothing in this provision is intended to restrict Executive from submitting any matter to an administrative agency
with jurisdiction over such matter. 
 The Executive and the Company agree that any disputes related to or arising out of the
Executive’s employment with the Company will be determined by arbitration in accordance with the then-current JAMS employment arbitration rules and procedures, except as modified herein. The arbitration will be conducted by a sole neutral
arbitrator who has had both training and experience as an arbitrator of general employment and commercial matters and who is, and for at least ten (10) years has been, a partner, a shareholder, or a member in a law firm. If the Company and
Executive cannot agree on an arbitrator, then the arbitrator will be selected by JAMS in accordance with Rule 12 of the JAMS employment arbitration rules and procedures. Reasonable discovery will be permitted by both parties and the arbitrator may
decide any issue as to discovery. The arbitrator may decide any issue as to whether or as to the extent to which any dispute is subject to arbitration in this Section V and the arbitrator may award any relief permitted by law. The arbitrator must
render the award in writing, including an explanation of the reasons for the award. Judgment upon the award may be entered by any court having jurisdiction of the matter, and the decision of the arbitrator will be final and binding. The parties
hereto hereby waive to the fullest extent permitted by law any rights to appeal or to review of such award by any court. The statute of limitations applicable to the commencement of a lawsuit will apply to the commencement of an arbitration under
Section V of this Agreement. At the request of any party, the arbitrator, attorneys, parties to the arbitration, witnesses, experts, court reporters or other persons present at the arbitration shall agree in writing to maintain the strict
confidentiality of the arbitration proceedings. The arbitrator’s fees and cost of the Arbitration will be paid in full by the Company, unless Executive agrees in writing to pay some or all of such fees. 
 B. Fees. Unless otherwise agreed, the prevailing party (if a prevailing party is determined to exist by the arbitrator or judge) will be entitled
to its costs and attorneys’ fees, expert fees incurred in any arbitration or other proceeding relating to the interpretation or enforcement of this Agreement, but not including the arbitrator’s fees and JAMS cost paid by the Company under
Paragraph A. 
 C. Acknowledgement. EXECUTIVE HAS READ AND UNDERSTANDS THIS SECTION V, WHICH DISCUSSES ARBITRATION. EXECUTIVE
UNDERSTANDS THAT BY SIGNING THIS AGREEMENT, EXECUTIVE AGREES TO SUBMIT ANY CLAIMS ARISING OUT OF, RELATING TO, OR IN CONNECTION WITH THIS AGREEMENT, OR THE INTERPRETATION, VALIDITY, CONSTRUCTION, PERFORMANCE, BREACH OR TERMINATION THEREOF TO
ARBITRATION, AND THAT THE PROVISIONS SET FORTH IN THIS SECTION V CONSTITUTE A WAIVER OF EXECUTIVE’S RIGHT TO A JURY TRIAL. 
  

 NOVABAY PHARMACEUTICALS, INC. 

					
	5980 Horton St., Ste 550	 	 	  	 (510) 595-1100 x150
	Emeryville, CA 94608	 	 	  	 Fax: (510) 740-3629

 rnajafi@novabaypharma.com 

 D. No Duty to Mitigate. Executive is under no contractual or legal obligation to mitigate
Executive’s damages in order to receive the severance benefits provided in this Agreement. 
  

	VI.	LEGAL ADVICE. 

 Executive acknowledges that an
opportunity has been afforded to Executive to consult with legal counsel with respect to this Agreement and that no individual representing the Company has given legal advice with respect to this Agreement. 
  

	VII.	MISCELLANEOUS AND CONSTRUCTION. 

 Except as
otherwise specifically provided herein, this Agreement: 
 A. and any benefits or obligations herein may not be assigned or delegated by

 Executive (but may be so assigned or delegated by the Company); 
 B. contains the entire understandings of the parties as to its subject matter, and replaces and supersedes any existing employment agreement and any and
all contrary prior understandings or agreements; 
 C. may be amended or modified only by a written amendment or modification signed by the
Company and Executive; 
 D. is made in, and shall be construed under the laws of, the State of California; 
 E. inures to the benefit of, and is binding upon, the permitted successors, assigns, distributees, personal representatives, heirs and other
successors-in-interest to and of the parties hereto; 
 F. shall not be interpreted by reference to any of the captions or headings of the
paragraphs herein, which captions or headings have been inserted for convenience purposes only; 
 G. shall be fully effectuated in
accordance with its tenor, effect and purposes by each of the parties hereto by executing such further documents or taking such other actions as may be reasonably requested by the other party hereto; and 
 H. shall be interpreted, as to its remaining provisions, to be fully lawful and operative, to the extent reasonably required to fulfill its principal
tenor, effect and purposes, in the event that any provision either is found by any court of competent jurisdiction to be unlawful or inoperative or violates any statutory or legal requirement, and the balance of the Agreement shall be interpreted as
if such provision were so excluded and shall be enforceable in accordance with its terms. 
  

 NOVABAY PHARMACEUTICALS, INC. 

					
	5980 Horton St., Ste 550	 	 	  	 (510) 595-1100 x150
	Emeryville, CA 94608	 	 	  	 Fax: (510) 740-3629

 rnajafi@novabaypharma.com 

 I. may be executed in more than one counterpart, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. 
 [signature page to follow] 
  

 NOVABAY PHARMACEUTICALS, INC. 

					
	5980 Horton St., Ste 550	 	 	  	 (510) 595-1100 x150
	Emeryville, CA 94608	 	 	  	 Fax: (510) 740-3629

 rnajafi@novabaypharma.com 

 IN WITNESS WHEREOF, the Company and Executive have executed this Agreement as of the day and year first
above written. 
  

			
	COMPANY:
	
	NOVABAY PHARMACEUTICALS, INC.
		
	By:	 	/s/ Ron Najafi
	Name:	 	Ron Najafi, Ph.D.
	Title:	 	President and CEO
	Address:	 	5980 Horton Street, Suite 550
		 	Emeryville, CA 94608
	Fax No.:	 	(510) 740-3629
	E-mail:	 	rnajafi@novabaypharma.com
	
	EXECUTIVE:
		
		 	/s/ Thomas J. Paulson
		 	THOMAS J. PAULSON
		
	Address:	 	557 Creedon Circle
		 	Alameda, CA 94502
	Telephone No.	 	(510) 543-5601
	E-mail:	 	tpaulson@thepaulsongroup.com

  

 NOVABAY PHARMACEUTICALS, INC. 

					
	5980 Horton St., Ste 550	 	 	  	 (510) 595-1100 x150
	Emeryville, CA 94608	 	 	  	 Fax: (510) 740-3629

 rnajafi@novabaypharma.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}]]